Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 17/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19793199 | 0.84 | GRM4 (0.74) | GRM4CYP1A2EPHX2 | |
| SCHEMBL19793089 | 0.81 | GRM4 (0.41) | GRM4CYP1A2TRPA1 | |
| SCHEMBL19793200 | 0.81 | GRM4 (0.76) | GRM4CYP1A2 | |
| SCHEMBL19793214 | 0.81 | GRM4 (0.46) | GRM4CYP1A2TRPA1EPHX2 | |
| SCHEMBL19793073 | 0.80 | GRM4 (0.50) | GRM4CYP1A2 | |
| SCHEMBL19793216 | 0.78 | GRM4 (0.73) | GRM4CYP1A2TRPA1EPHX2 | |
| SCHEMBL19793037 | 0.77 | GRM4 (0.57) | GRM4CYP1A2 | |
| SCHEMBL19793139 | 0.76 | GRM4 (1.00) | GRM4CYP1A2 | |
| SCHEMBL19793076 | 0.76 | GRM4 (0.63) | GRM4CYP1A2EPHX2 | |
| SCHEMBL19793057 | 0.76 | GRM4 (0.43) | GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRM1 | GRM4 2/4885CYP1A2 3387/4885TRPA1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.